Effect of Evolocumab on Coronary Plaque Characteristics: a Multimodality Imaging Study
Latest Information Update: 28 Jan 2025
At a glance
- Drugs Evolocumab (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- Acronyms YELLOW III
- 13 Nov 2023 Status changed from active, no longer recruiting to completed.
- 09 Mar 2023 Planned End Date changed from 1 Feb 2024 to 1 Oct 2023.
- 09 Mar 2023 Status changed from recruiting to active, no longer recruiting.